Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Versum Materials Reports Fiscal Second Quarter 2019 Financial Results

Published

on

Reading Time: 13 minutes

Fiscal Second Quarter 2019 Financial Highlights

  • Sales of $326 million, Net Income of $50 million, or diluted EPS of
    $0.46
  • Adjusted EBITDA of $110 million, or Adjusted EBITDA Margin of 34%
  • Adjusted Net Income of $62 million, or diluted EPS of $0.57
  • Entered definitive merger agreement with Merck KGaA

The results in this press release include Non-GAAP financial
measures. Refer to the section entitled “Non-GAAP Financial Measures.”

TEMPE, Ariz.–(BUSINESS WIRE)–Versum Materials, Inc. (NYSE: VSM), a leading specialty materials
and equipment supplier to the semiconductor industry, today reported
results for the fiscal second quarter ended March 31, 2019.

Sales were $326.2 million, compared to $340.7 million in the prior year
quarter. Net income was $50.4 million, or $0.46 per diluted share,
compared to $0.56 per diluted share in the prior year, primarily due to
softer revenue, transaction related expenses and higher taxes. Adjusted
Net Income was $62.4 million, or $0.57 per diluted share, compared to
$0.59 in the prior year. Adjusted EBITDA was $110.1 million, flat versus
prior year, with favorable costs offsetting the revenue softness.

Guillermo Novo, Versum Materials’ President and Chief Executive Officer
said, “I am extremely proud of our team for delivering solid adjusted
EBITDA results in a moderating demand and investment environment. Our
results demonstrate the resiliency of our business portfolio and our
commitment to operating discipline. During the quarter, we continued to
advance our technology positions for new nodes and executed on our
capital projects, both which we believe will accelerate our growth in
Fiscal 2020.”

On April 12, 2019, Versum Materials announced entry into a definitive
merger agreement with Merck KGaA. The business combination is expected
to create a leading electronic materials player focused on the
semiconductor and display industries. The combined companies and their
customers and employees will benefit from increased scale, product
portfolio, innovation and services depth, globally.

Mr. Novo added, “We are all very excited about joining Merck KGaA, a
company with a long history of commitment to technology and innovation.
Like all of us at Versum, they share our belief in the exciting future
of the semiconductor industry. We look forward to combining our
technology and infrastructure capabilities to offer a greater depth and
breadth of materials technologies to our customers. We expect to play an
even more critical role in our industry.”

No Fiscal Year 2019 Outlook or Earnings Conference Call

In light of the announced transaction with Merck KGaA, Versum Materials
will not provide or update annual financial guidance and will not hold a
conference call to review quarterly earnings results. The parties
continue to work toward closing in the second half of 2019 and the
transaction is subject to the approval of Versum stockholders at a
Versum special meeting, regulatory clearances and the satisfaction of
other customary closing conditions.

     

Table 1: Fiscal Second Quarter Fiscal Year 2019 Financial
Highlights

 
Three Months Ended March 31,
2019       2018       % Change
(In millions, except percentages and per share data)
Sales $ 326.2 $ 340.7 (4 )%
Operating Income(A) 82.6 89.6 (8 )%
Net Income 50.4 61.6 (18 )%
Net Income Margin 15.5 % 18.1 % -260 bps
Diluted Earnings Per Share 0.46 0.56 (18 )%
Adjusted Net Income 62.4 64.7 (4 )%
Adjusted Net Income Margin 19.1 % 19.0 % 10 bps
Adjusted Diluted Earnings Per Share 0.57 0.59 (3 )%
Adjusted EBITDA(A) 110.1 110.1 %
Adjusted EBITDA Margin 33.8 % 32.3 % 150 bps
 
Year to Date Cash Flows from Operations 73.3 56.5 30 %
Year to Date Capital Expenditures 45.0 65.1 (31 )%
       

(A) – The fiscal second quarter ended March 31, 2018 amounts have
been recast to reflect the retrospective application of the
company’s change in classification of the non-service components
of net periodic pension cost.

Business Segment Results

Materials

Sales were $216.5 million, compared to $218.9 million in the prior year
as volume growth in the Materials segment was offset by negative
price/mix and currency impacts. Overall performance for the quarter was
impacted by softer demand in foundry and inventory management by memory
customers. We made further progress on the introduction of new
technologies for both new and legacy nodes, including ION‐X dopant gas
customer qualifications and strategic Process of Record (POR) wins in
aminosilane and cobalt precursors. We continued to advance our capital
projects, including starting slurry production in Korea and advancing
the qualification of new Hometown NF3 production.

Operating income was $65.4 million, compared to $71.7 million in the
prior year. Segment Adjusted EBITDA was $78.2 million, compared to $83.3
million in the prior year due primarily to negative price/mix and
increased manufacturing costs related to the start-up of capital
investments.

Delivery Systems & Services (DS&S)

Delivery Systems posted another strong quarter with sales of $109.1
million, driven by the diversity of equipment, installation projects and
services portfolio. This compared to $121.1 million in the prior year,
impacted by softer demand and project timing.

Operating income was $34.9 million, compared to $32.9 million in the
prior year. Segment Adjusted EBITDA was $35.6 million, compared to $33.3
million in the prior year, as favorable product mix, installation
project completions and disciplined cost management more than offset
softer equipment demand.

Table 2: Segment Sales

  Three Months Ended March 31,
  2019       2018     % Change
(In millions, except percentages)
Materials $ 216.5 $ 218.9 (1 )%
DS&S 109.1 121.1 (10 )%
Corporate   0.6     0.7   (14 )%
Total Versum Materials Sales $ 326.2   $ 340.7   (4 )%
 

Table 3: Segment Operating Income to Segment Adjusted EBITDA

 
Three Months Ended March 31,
  2019     2018   % Change
(In millions, except percentages)
Materials
Operating income(A) $ 65.4 $ 71.7 (9 )%
Add: Depreciation and amortization   12.8     11.6   10 %
Segment Adjusted EBITDA(A) $ 78.2   $ 83.3   (6 )%
Segment Adjusted EBITDA Margin(B) 36 % 38 %
DS&S
Operating income $ 34.9 $ 32.9 6 %
Add: Depreciation and amortization   0.7     0.4   75 %
Segment Adjusted EBITDA $ 35.6   $ 33.3   7 %
Segment Adjusted EBITDA Margin(B) 33 % 27 %
Corporate
Operating loss(A) $ (3.9 ) $ (6.8 ) (43 )%
Add: Depreciation and amortization   0.2     0.3   (33 )%
Segment Adjusted EBITDA(A) $ (3.7 ) $ (6.5 ) (43 )%
 

(A) The fiscal second quarter ended March 31, 2018 amounts have
been recast to reflect the retrospective application of the
company’s change in classification of the non-service components
of net periodic pension cost.

 

(B) Segment Adjusted EBITDA margin is calculated by dividing
Segment Adjusted EBITDA by sales.

 

Table 4: Reconciliation of Segment Operating Income to Total
Versum Materials Operating Income

 
Three Months Ended March 31,
  2019     2018   % Change
(In millions, except percentages)
Materials(A) $ 65.4 $ 71.7 (9 )%
DS&S 34.9 32.9 6 %
Corporate(A)   (3.9 )   (6.8 ) (43 )%
Total Segment Operating Income(A) 96.4 97.8 (1 )%
Less: Business separation, restructuring and cost reduction actions   13.8     8.2   68 %
Total Versum Materials Operating Income(A) $ 82.6   $ 89.6   (8 )%
 

(A) – The fiscal second quarter ended March 31, 2018 amounts have
been recast to reflect the retrospective application of the
company’s change in classification of the non-service components
of net periodic pension cost.

About Versum Materials

Versum Materials, Inc. (NYSE: VSM) is a leading global specialty
materials company providing high-purity chemicals and gases, delivery
systems, services and materials expertise to meet the evolving needs of
the global semiconductor and display industries. Derived from the Latin
word for “toward,” the name “Versum” communicates the company’s deep
commitment to helping customers move toward the future by collaborating,
innovating and creating cutting-edge solutions.

A global leader in technology, quality, safety and reliability, Versum
Materials is one of the world’s leading suppliers of next-generation CMP
slurries, ultra-thin dielectric and metal film precursors, formulated
cleans and etching products, and delivery equipment that has
revolutionized the semiconductor industry. Versum reported fiscal year
2018 annual sales of about US $1.4 billion, has approximately 2,300
employees and operates fifteen manufacturing and seven research and
development facilities in Asia and North America. It is headquartered in
Tempe, Arizona. Versum Materials had operated for more than three
decades as a division of Air Products and Chemicals, Inc. (NYSE: APD).

For additional information, please visit http://www.versummaterials.com.

Non-GAAP Financial Measures

This earnings press release includes “non-GAAP financial measures,”
including Adjusted Net Income, Adjusted Net Income Margin, Adjusted
Diluted Earnings Per Share, Adjusted EBITDA, Segment Adjusted EBITDA,
Adjusted EBITDA margin, and Segment Adjusted EBITDA margin. Adjusted Net
Income is net income excluding certain disclosed items which we do not
believe to be indicative of underlying business trends, including
business separation, restructuring and cost reduction actions, net of
tax, the write-off of financing costs, net of tax, and the impact of the
Tax Act. Adjusted Diluted Earnings Per Share uses Adjusted Net Income
but otherwise uses the same calculation used in arriving at diluted
earnings per share, the most directly comparable GAAP financial measure.
Adjusted EBITDA is net income excluding certain disclosed items which we
do not believe to be indicative of underlying business trends, including
interest expense, the write-off of financing costs, non-service
components of net periodic pension cost, income tax provision,
depreciation and amortization expense, non-controlling interests, and
business separation, restructuring and cost reduction actions. Segment
Adjusted EBITDA is segment operating income excluding segment
depreciation and amortization expense. Adjusted Net Income Margin,
Adjusted EBITDA margin and Segment Adjusted EBITDA margin are calculated
by dividing Adjusted Net Income, Adjusted EBITDA and Segment Adjusted
EBITDA, respectively, by sales. In the accompanying tables, Versum
Materials has provided reconciliations of net income to Adjusted EBITDA
(see Appendix Table A-1), net income to Adjusted Net Income (see
Appendix Table A-2), diluted EPS to Adjusted Diluted EPS (see Appendix
A-3) and of segment operating income (loss) to Segment Adjusted EBITDA
by Quarter (see Appendix Table A-5), in each case the most directly
comparable GAAP financial measure. We encourage investors to read these
reconciliations.

The presentation of these non-GAAP financial measures is intended to
enhance the usefulness of financial information by providing measures
which management uses internally to evaluate our operating performance.
We use non-GAAP measures to assess our operating performance by
excluding certain disclosed items that we believe are not representative
of our underlying business. Management may use these non-GAAP measures
to evaluate our performance period over period and relative to
competitors in our industry, to analyze underlying trends in our
business and to establish operational budgets and forecasts or for
incentive compensation purposes. We use Adjusted EBITDA to calculate
performance-based cash bonuses. We use Segment Adjusted EBITDA as the
primary measure to evaluate the ongoing performance of our business
segments.

We believe non-GAAP financial measures provide security analysts,
investors and other interested parties with meaningful information to
understand our underlying operating results and to analyze financial and
business trends; enables better comparison to peer companies; and allows
us to provide a long-term strategic view of the business going forward.
These non-GAAP financial measures should not be viewed in isolation, are
not a substitute for GAAP measures, and have limitations which include
but are not limited to the following: (a) Adjusted Net Income and
Adjusted EBITDA exclude expenses related to business separation,
restructuring and cost reduction actions and the write-off of financing
costs, each of which we do not consider to be representative of our
underlying business operations, however, these disclosed items represent
costs to Versum Materials; (b) Adjusted EBITDA is not intended to be a
measure of cash available for management’s discretionary use, as it does
not consider certain cash requirements such as interest payments, tax
payments and debt service requirements; (c) though not business
operating costs, interest expense and income tax provision represent
ongoing costs of Versum Materials; (d) depreciation and amortization
charges represent the wear and tear or reduction in value of the plant,
equipment, and intangible assets which permit us to manufacture and
market our products; and (e) other companies may define non-GAAP
measures differently than we do, limiting their usefulness as
comparative measures. A reader may find any one or all of these items
important in evaluating our performance. Management compensates for the
limitations of using non-GAAP financial measures by using them only to
supplement our GAAP results to provide a more complete understanding of
the factors and trends affecting our business. In evaluating these
non-GAAP financial measures, the reader should be aware that we may
incur expenses similar to those eliminated in this presentation in the
future.

A reconciliation of net income to Adjusted EBITDA as forecasted for 2019
is not provided. Versum Materials does not forecast net income as it
cannot, without unreasonable effort, estimate or predict with certainty
various components of net income. These components include restructuring
and other income or charges to be incurred in 2019 as well as the
related tax impacts of these items. Additionally, discrete tax items
could drive variability in our forecasted effective tax rate. All of
these components could significantly impact net income. Further, in the
future, other items with similar characteristics to those currently
included in Adjusted EBITDA that have a similar impact on comparability
of periods, and which are not known at this time, may exist and impact
Adjusted EBITDA.

Forward-Looking Information

This press release contains “forward-looking statements” within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements may be
identified by references to future periods and include statements about
our financial outlook or guidance; statements about our expectations or
predictions of future financial or business performance or conditions;
statements about our anticipated growth, profitability and margins; our
ability to compete successfully as a leading materials supplier to the
semiconductor industry and obtain next generation node opportunities;
and other matters. The words “believe,” “expect,” “anticipate,”
“estimate,” “continue,” “could,” “intend,” “may,” “plan,” “potential,”
“predict,” “seek,” “should,” “forecast,” “guidance,” “outlook,”
“opportunity” and similar expressions, among others, generally identify
forward-looking statements, which are based on management’s reasonable
expectations and assumptions as of the date the statements were made.
These statements involve a number of risks, uncertainties and other
factors that could cause actual results to differ materially, including
without limitation the following: Merck KGaA’s ability to successfully
complete the proposed acquisition of Versum or realize the anticipated
benefits of the proposed transaction in the expected time-frames or at
all; Merck KGaA’s ability to successfully integrate Versum’s operations
into those of Merck KGaA; such integration may be more difficult,
time-consuming or costly than expected; the failure to obtain Versum’s
stockholders’ approval of the proposed transaction; the failure of any
of the conditions to the proposed transaction to be satisfied; revenues
following the proposed transaction may be lower than expected; operating
costs, customer loss and business disruption (including, without
limitation, difficulties in maintaining relationships with employees,
customers, clients or suppliers) may be greater than expected following
the proposed transaction; the retention of certain key employees at
Versum; risks associated with the disruption of management’s attention
from ongoing business operations due to the proposed transaction; the
outcome of any legal proceedings related to the proposed transaction;
the impact of the proposed transaction on Versum’s credit rating; the
parties’ ability to meet expectations regarding the timing and
completion of the proposed transaction; delays in obtaining any
approvals required for the proposed transaction or an inability to
obtain them on the terms proposed or on the anticipated schedule; the
impact of indebtedness incurred by Merck KGaA in connection with the
proposed transaction; the effects of the business combination of Versum
and Merck KGaA, including the combined company’s future financial
condition, operating results, strategy and plans; events beyond our
control such as acts of terrorism; product supply versus demand
imbalances in the semiconductor industry or in certain geographic
markets may decrease the demand for our goods and services; our
concentrated customer base; the dependence of our DS&S segment upon the
capital expenditure cycles of our customers; our ability to continue
technological innovation and successfully introduce new products to meet
the evolving needs of our customers; our ability to protect and enforce
our intellectual property rights and to avoid violating any third party
intellectual property or technology rights; unexpected interruption of
or shortages in our raw material supply; inability of sole source,
limited source or qualified suppliers to deliver to us in a timely
manner or at all; hazards associated with specialty chemical
manufacturing, such as fires, explosions and accidents, could disrupt
operations; increased competition and new product development by our
competitors, changing customer needs and price increases in materials
and components; operational, political and legal risks of our
international operations; increased costs due to trade wars and the
implementation of tariffs; the impact of changes in tax laws; the impact
of changes in environmental and health and safety regulations,
anticorruption enforcement, sanctions, import/export controls, tax and
other legislation and regulations in the U.S. and other jurisdictions in
which Versum Materials and its affiliates operate; our available cash
and access to additional capital may be limited by substantial leverage
and debt service obligations; possible liability for contamination,
personal injury or third party impacts if hazardous materials are
released into the environment; cyber security threats may compromise our
data or disrupt our information technology applications or services;
fluctuation of currency exchange rates; costs and outcomes of litigation
or regulatory investigations; the timing, impact, and other
uncertainties of future acquisitions or divestitures; and other risks,
uncertainties and factors discussed in the company’s Form 10-Qs, Form
10-K and in the company’s other filings with the U.S. Securities and
Exchange Commission available at www.sec.gov
or in materials incorporated therein by reference or in Merck KGaA’s
public reports which are available on the Merck KGaA, Darmstadt,
Germany, website at www.emdgroup.com.
Any forward-looking statement in this press release speaks only as of
the date on which it is made. The company assumes no obligation to
update or revise any forward-looking statements.

         

Versum Materials, Inc.

CONSOLIDATED INCOME STATEMENTS

(Unaudited)

 
Three Months Ended March 31, Six Months Ended March 31,
2019   2018   % Change 2019   2018   % Change
(In millions, except per share data and percentages)
Sales $ 326.2 $ 340.7 (4 )% $ 665.7 $ 671.5 (1 )%
Cost of sales (A),(B) 189.8 195.8 (3 )% 385.9 387.0 %
Selling and administrative (B) 32.6 36.5 (11 )% 68.1 71.8 (5 )%
Research and development 11.1 11.1 % 24.0 23.8 1 %
Business separation, restructuring and cost reduction actions 13.8 8.2 68 % 14.9 10.0 49 %
Other (income) expense, net (3.7 ) (0.5 ) NM (5.6 )   NM
Operating Income (B) 82.6 89.6 (8 )% 178.4 178.9 %
Interest expense 13.2 11.9 11 % 26.0 23.2 12 %
Write-off of financing costs NM 2.1 NM
Non-service components of net periodic pension cost(B) 0.2   0.2   % 0.4   0.4   %
Income Before Taxes 69.2 77.5 (11 )% 152.0 153.2 (1 )%
Income tax provision (A) 18.1   14.2   27 % 37.8   69.2   (45 )%
Net Income 51.1 63.3 (19 )% 114.2 84.0 36 %
Less: Net Income Attributable to Non-Controlling Interests 0.7   1.7   (59 )% 2.7   3.7   (27 )%
Net Income Attributable to Versum $ 50.4   $ 61.6   (18 )% $ 111.5   $ 80.3   39 %
Net income attributable to Versum per common share:
Basic $ 0.46   $ 0.57   (19 )% $ 1.02   $ 0.74   38 %
Diluted $ 0.46   $ 0.56   (18 )% $ 1.01   $ 0.73   38 %
Shares used in computing per common share amounts:
Basic 109.1 108.9 % 109.1 108.9 %
Diluted 110.0 109.7 % 109.9 109.8 %
  (A) – The fiscal year to date ended March 31, 2018 amounts have been
recast to reflect the retrospective application of the company’s
election to change its inventory valuation method of accounting for
its U.S. inventories from the LIFO method to the FIFO method, which
resulted in a decrease in Cost of sales of $0.2 million for the
fiscal year to date ended March 31, 2018 and an increase in the
Income tax provision of $0.1 million for the fiscal year to date
ended March 31, 2018.
 
(B) – The fiscal second quarter and year to date ended March 31,
2018 amounts have been recast to reflect the retrospective
application of the company’s change in classification of the
non-service components of net periodic pension cost. This resulted
in a decrease in Cost of sales of $0.1 million and $0.3 million for
the fiscal second quarter and year to date ended March 31, 2018,
respectively, a decrease in Selling and administrative of $0.1
million for the fiscal second quarter and year to date ended March
31, 2018, an increase to Operating Income of $0.2 million and $0.4
million for the fiscal second quarter and year to date ended March
31, 2018, respectively, and an increase to non-service components of
net periodic pension costs of $0.2 million and $0.4 million for the
fiscal second quarter and year to date ended March 31, 2018,
respectively.
         

Versum Materials, Inc.

CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
March 31, 2019

September 30,
2018

(In millions)

Assets

Current Assets
Cash and cash items $ 390.8 $ 399.8
Short-term investment 11.4
Trade receivables, net 188.1 184.4
Inventories 203.1 177.1
Contracts in progress, less progress billings 32.0 20.3
Prepaid expenses 21.1 13.6
Other current assets 19.3   17.9  
Total Current Assets 865.8   813.1  
Plant and equipment, net 422.3 405.1
Goodwill 182.5 183.0
Intangible assets, net 60.7 63.5
Other non-current assets 35.9   40.6  
Total Non-Current Assets 701.4   692.2  
Total Assets $ 1,567.2   $ 1,505.3  

Liabilities and Stockholders’ Deficit

Current Liabilities
Payables and accrued liabilities $ 122.8 $ 138.6
Accrued income taxes 35.4 43.3
Short-term borrowings 0.3
Current portion of long-term debt 5.8   5.8  
Total Current Liabilities 164.3   187.7  
Long-term debt 972.2 974.2
Noncurrent income tax payable 32.3 37.3
Deferred tax liabilities 38.9 41.3
Other non-current liabilities 53.6   52.4  
Total Non-Current Liabilities 1,097.0   1,105.2  
Total Liabilities 1,261.3   1,292.9  
Stockholders’ Equity
Common stock 109.2 109.0
Capital in excess of par 8.7 6.1
Retained earnings 175.5 81.6
Accumulated other comprehensive income (loss) (23.8 ) (18.2 )
Total Versum’s Stockholders’ Equity 269.6 178.5
Non-Controlling Interests 36.3   33.9  
Total Stockholders’ Equity 305.9   212.4  
Total Liabilities and Stockholders’ Equity $ 1,567.2   $ 1,505.3  

Contacts

Investor Inquiries:
Soohwan Kim, CFA, (602)-282-0957
[email protected]

Media Inquiries:
Tiffany Elle, (480)-282-6475
[email protected]

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading

Cannabis

Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania